<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO> WSJ880511-0058 </DOCNO><HL> Business Brief: Eastman Kodak Co. </HL><SO> </SO><CO> EK IMNX AREL </CO><IN> TNM </IN><TEXT>   Eastman Kodak Co., Rochester, N.Y., said it will invest $20 million in Immunex Corp., as part of an agreement to expand drug research by Immunology Ventures, the partnership created by the two companies in January 1986.    As part of the agreement, Seattle-based Immunex will hold U.S. marketing rights for therapeutic drugs developed through the program, while Kodak will have marketing rights for the rest of the world.    Also as part of the agreement, Immunex will buy out Kodak's share of the current joint venture's manufacturing plant. Terms of the buy-out weren't disclosed.    Kodak said it would buy from Immunex 20,000 shares of its Series A convertible preferred stock for $20 million. The preferred shares will carry a 6% cumulative dividend and be convertible into Immunex common stock over a period of five years.    Separately, Alpharel Inc. signed an agreement to buy $10 million in optical disk products during the next two years from Kodak's mass-memory division. </TEXT></DOC>